Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitaxsentan Monotherapy vs Combination with Sildenafil in PAH
NCT00796666Phase 3Terminated
- Sponsor
- Pfizer
- Start
- May 2009
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of sitaxsentan and ASP-001 in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Pfizer. Primary endpoint: Time to Clinical Worsening at 24 weeks. Started May 2009; status: terminated.
02
Drugs
sitaxsentanASP-001
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00796666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00796666.